Delcath: The Market Still Sees a Burner. The Margins Say Otherwise.

The market is still pricing Delcath Systems as a niche biotech fighting for survival. That story was plausible two years ago — a small player with a single FDA approval, a reimbursement question mark, and cash burn keeping investors awake. But HEPZATO has been the company's only product the entire time, and it now prints at a 90% gross margin while the company generates net income on a quarterly basis. The operating setup has changed. The market hasn't caught up.

Delcath reported $29.1 million in revenue for Q2 2026, up from $24.2 million a year earlier. Almost all of it — $27.1 million — came from HEPZATO KIT, the only FDA-approved liver-directed therapy for metastatic uveal melanoma with hepatic metastases. HEPZATO procedure volume grew roughly 30% year over year. Gross margins improved to 90% from 86% in the prior-year quarter. The company posted net income of $2.7 million. It holds $95.9 million in cash and investments and carries no debt.

Management raised full-year 2026 revenue guidance to $104–$108 million, implying mid-20s percent growth over 2025's approximately $85 million. That is a step down from the 140% procedure volume surge Delcath logged in 2025 versus 2024, but deceleration from a tripling base is mechanical, not concerning — the company is adding treatment centers, not losing them. Active centers went from 25 in late 2025 to 31 today, with a target of 37 by year-end.

What matters is what happens to that revenue after the product ships. Gross margins in the 86–89% range are projected for the full year. HEPZATO is an almost pure margin machine: it's a melphalan delivery system — essentially a specialized catheter that isolates the liver during infusion, allowing high-dose chemotherapy to be concentrated in the organ while minimizing systemic toxicity. The drug itself is a commodity chemical; the proprietary Hepatic Delivery System is where the economics live. That's why gross margins are already at levels more typical of mature device franchises than early-stage specialty pharma.

The company expects positive adjusted EBITDA for the full year 2026. Delcath isn't on the path to profitability anymore. It's there.

This is the inflection the market hasn't priced. The stock trades around $15, for a market cap of roughly $454 million — about 4.2 to 4.4 times forward revenue. With enterprise value (market cap minus $95.9 million in net cash) around $358 million, the multiple compresses to 3.3–3.4 times revenue. A business growing revenue in the mid-20s percent range, printing 90% gross margins, and turning positive on an operating-cash basis at 3.4x EV/revenue is priced like it's still burning through its war chest.

The old worries have either resolved or lost their bite. Reimbursement — once the central risk — moved in Delcath's favor when CMS granted New Technology Add-on Payment status for HEPZATO in August 2024, providing additional Medicare coverage for inpatient procedures and signaling clinical acceptance. The company also entered a national Medicaid Drug Rebate Agreement in mid-2025, removing the patchwork-state negotiation headache that has stalled smaller specialty therapies before.

Center expansion is the growth engine, and it's a clean one. Each new treatment center represents trained physicians, established protocols, and recurring procedure volume. The company is also pushing HEPZATO into combination use with systemic therapies for uveal melanoma, which management highlighted as strengthening physician confidence. A Phase 2 trial in HER2-negative metastatic breast cancer — the first patient dosed this year — opens the largest addressable liver-metastasis indication outside uveal melanoma. Investigator-initiated work in cutaneous melanoma with liver metastases was presented at ASCO 2026. None of these are revenue today, but they are the pipeline optionality that makes the current multiple look increasingly backward-looking.

The counterargument is straightforward: HEPZATO treats a rare disease in a narrow patient population. Even at 37 centers, the addressable market is limited. Procedure volume decelerated from 140% growth in 2025 to the mid-20s percent range in 2026 guidance. R&D and SG&A spending pushed adjusted EBITDA down to $7.6 million in Q2 from $9.8 million a year earlier. The cash flow story improves only if those spending levels don't keep rising.

That's fair. But the question isn't whether the growth rate stays triple-digit. It's whether a 90%-margin revenue stream on a $100+ million base generates enough cash to make the stock look different from the sell-side valuation. At $104–108 million in revenue and 86–89% gross margin, gross profit runs roughly $90–96 million. Even if operating expenses (R&D, SG&A, and other costs) hold at $50–60 million — the mid-point implied by recent quarters — operating income approaches $30–40 million. A forward EV/EBIT multiple in the 9–12x range — modest for a growth device company but well within what the market pays for profitable specialty medtech — implies enterprise value of $270–480 million. Adding back net cash, that's an equity value range of roughly $370–580 million, or $12–$19 per share on roughly 30 million shares outstanding.

That framework puts the current price at the floor of where the stock should trade if the operating picture holds. A $18–$20 target over the next 12 months is defensible if Delcath delivers guided revenue, maintains gross margins in the stated range, and hits the 37-center goal. It doesn't require the pipeline programs to reach conclusions. It just requires the core business to execute.

The tripwire is simpler than the target. If HEPZATO revenue growth falls below high-teens percent, if gross margins crack below 80%, or if the company misses positive full-year adjusted EBITDA, the inflection thesis loses its foundation. The center-expansion story also breaks if active sites stagnate below 30 by year-end, suggesting adoption friction management hasn't disclosed.

The setup here isn't about excitement. It's about a business that looks harder to dismiss every quarter as the numbers accumulate. The market is still pricing the old risk profile. The margins already say something different.

BTIG raised its price target to $21 in the wake of Q2 results, citing the guidance raise and margin profile. Clear Street sits at $27. Craig-Hallum is at $18. The range reflects the same tension: the math supports rerating, but the small-population narrative keeps a lid on conviction.

Discipline over ego. If the numbers keep running like this, the stock becomes obvious. If they don't, the tripwire is clear.